# A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

> **NCT01656811** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 146 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** levalbuterol 90 mcg
- **DRUG:** levalbuterol 180 mcg
- **DRUG:** racemic albuterol 180 mcg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01656811
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2002-07
- **Final completion:** 2002-07
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2012-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01656811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01656811, "A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01656811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*